Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 77, Issue 1, 1997, Pages

  Poovorawan, Yong ^a,d   Sanpavat, Suvimol ^b   Chumdermpadetsuk, Saowani ^b   Safary, Assad ^c  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b Department of Paediatrics ^*

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Boosters; Hepatitis B vaccine; Long term efficacy; Transmission

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

EID: 0031418940     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.77.1.F47     Document Type: Article

References (25)

1. Moradpour D, Wands JR. Understanding hepatitis B infection. N Engl J Med 1995; 332:1092-3.
2. Anonymous. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull WHO 1988; 66:443.
3. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of hepatitis B by immunisation: global perspectives. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988: 967-9.
4. Ghendon Y. Perinatal transmission of hepatitis B virus in high incidence countries. J Virol Methods 1987; 17:69-79.
5. Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EC, Gerin JL, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976; 295:909-13.
6. Hindman SH, Gravelle CR, Murphy BL, Bradley DW, Budge WR, Maynard JE. "e" antigen, Dane particles and serum DNA polymerase activity in HBsAg carriers. Ann Intern Med 1976; 85:458-60.
7. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136:571-6.
8. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105:94-8.
9. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292:771-4.
10. Beasley RP, Hwang L-Y, Lee GC-Y, Lan C-C, Roan C-H, Huang F-Y, et al. Prevention of perinatally transmitted hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; i:1099-102.
11. Wong VCW, Ip HMH, Reesink HW, Neo Lelie P, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984;i:921-6.
12. Xu Z-Y, Liu C-B, Francis DP, Purcell RH, Gun Z-L, Duan S-C, et al. United States-China Cooperative Study group on hepatitis B. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomised, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-8.
13. Pongpipat D, Suvatte V, Assateerawatts A. Perinatal transmission of hepatitis B virus in Thailand. Asian Pacific J Allergy Immunol 1985;3:191-3.
14. Lo K-J, Tsai Y-T, Lee S-D, Wu T-C, Wang J-Y, Chen G-H, et al. Immunoprophylaxis of infection with hepatitis B virus in infants bora to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985; 152:817-22.
15. Beasley RP, Hwang L-Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-90.
16. World Health Organisation. Expanded Programme on Immunisation. Global Advisory Group - Part II. Wkly Epidemiol Rec 1991;66:9-12.
17. Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapelière P, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11:816-21.
18. Stéphenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8(Suppl): 69-73.
19. Tong MJ, Poovorawan Y, Coursaget P. Immunoprophylaxis of neonates against hepatitis B. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore: Williams & Wilkins, 1991:849-55.
20. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis and Liver Disease. Proceedings of the 1982 International Symposium on Viral Hepatitis and Liver Disease. Philadelphia: Franklin Institute Press, 1982:451-66.
21. Lee P-I, Lee C-Y, Huang L-M, Chang M-H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995;126:716-21.
22. Assateerawatt A, Tanphaichitr VS, Suvatte V, Ingarm L. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. Asian Pacific J Allergy Immunol 1991;9:89-93.
23. Assateerawatt A, Suvatte V, Tanphaichitr VS. Long term efficacy of hepatitis B immunoprophylaxis in neonates at high risk: using different vaccine and schedule. J Med Assoc Thai 1992;75:328-36.
24. Stevens CE, Toy PT, Taylor PE, Lee T, Yip H-Y. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Paediatrics 1992;90:170-3.
25. Zhu Q-R, Gu X-H, Duan S-C, Xu H-F. Long-term immunogenicity and efficacy of recombinant yeast derived hepatitis B vaccine for interruption of mother-infant transmission of hepatitis B virus. Chinese Med J 1994; 107:915-8.